title: [Metabolic impact of androgen deprivation therapy for prostate cancer].
abstract: Because of the low mortality rates associated with prostate cancer, treatments long-term adverse effects constitute an important parameter in the management of patients. In particular, androgen deprivation has been shown to be linked to several metabolic disorders which are already frequent in men after age 60, such as weight and fat gain, insulin resistance likely to evolve into diabetes, and dyslipidemia. So far no consensus guidelines have been published regarding the screening and treatment of metabolic disorders in men with prostate cancer. It is essential to detect and manage these metabolic disorders, all the more so as they seem to be associated with an increased aggressiveness of prostate cancer. Here we report the development of a new questionnaire, which might contribute to the systematic management, and potentially the screening and treatment or the prevention of these metabolic disorders in patients with prostate cancer. In accordance with recent reviews and on the basis of experience, our French board of experts also recommends systematic screening and selective treatment for diabetes, regular follow-up of fasting glucose rates, lipid profile and blood pressure in all patients under long-term androgen deprivation treatment, as well as lifestyle changes (practice of exercise, nutritional habits).
authors.affiliation: Service Médecine Interne, Diabète et Maladies métaboliques, Clinique Médicale B, CHRU Strasbourg, Strasbourg, F-67000, France. emmanuel.andres@chru-strasbourg.fr
authors.forename: E
authors.initials: E
authors.lastname: Andrès
authors.forename: P
authors.initials: P
authors.lastname: Eschwege
authors.forename: H
authors.initials: H
authors.lastname: Lang
authors.forename: J-L
authors.initials: JL
authors.lastname: Moreau
authors.forename: D
authors.initials: D
authors.lastname: Peiffert
authors.forename: A
authors.initials: A
authors.lastname: Thiery-Vuillemin
authors.forename: F
authors.initials: F
authors.lastname: Kleinclauss
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008659:Metabolic Diseases / Q000139:chemically induced* / Q000453:epidemiology; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012307:Risk Factors; D011795:Surveys and Questionnaires
chemical_list: D000726:Androgen Antagonists